JP2018520685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520685A5 JP2018520685A5 JP2018502133A JP2018502133A JP2018520685A5 JP 2018520685 A5 JP2018520685 A5 JP 2018520685A5 JP 2018502133 A JP2018502133 A JP 2018502133A JP 2018502133 A JP2018502133 A JP 2018502133A JP 2018520685 A5 JP2018520685 A5 JP 2018520685A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- seq
- nos
- strand
- monomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 58
- 239000000178 monomer Substances 0.000 claims 23
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 3
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- IQFYYKKMVGJFEH-GJMOJQLCSA-N 1-[(2r,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-GJMOJQLCSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
- 208000035657 Abasia Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- XXYIANZGUOSQHY-XLPZGREQSA-N thymidine 3'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)C1 XXYIANZGUOSQHY-XLPZGREQSA-N 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193997P | 2015-07-17 | 2015-07-17 | |
| US62/193,997 | 2015-07-17 | ||
| PCT/US2016/042694 WO2017015175A1 (en) | 2015-07-17 | 2016-07-17 | Compositions and agents against hepatitis b virus and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520685A JP2018520685A (ja) | 2018-08-02 |
| JP2018520685A5 true JP2018520685A5 (cg-RX-API-DMAC7.html) | 2019-03-28 |
| JP6924744B2 JP6924744B2 (ja) | 2021-08-25 |
Family
ID=57775056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502133A Active JP6924744B2 (ja) | 2015-07-17 | 2016-07-17 | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170016000A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3325097B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6924744B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108136206B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016296592B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2996722A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI761311B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017015175A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013003520A1 (en) | 2011-06-30 | 2013-01-03 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| AU2016306275A1 (en) | 2015-08-07 | 2018-02-08 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for Hepatitis B virus infection |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| CR20210262A (es) | 2017-10-16 | 2022-06-27 | Hoffmann La Roche | MOLÉCULA DE ÁCIDOS NUCLEICOS PARA LA REDUCCIÓN DEL ARNm DE PAPD5 Y PAPD7 EN EL TRATAMIENTO DE LA INFECCIÓN DE LA HEPATITIS B (DIVISIONAL DEL EXPEDIENTE 2020-0205) |
| JP7273417B2 (ja) * | 2017-12-01 | 2023-05-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| JP7727308B2 (ja) | 2017-12-01 | 2025-08-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用 |
| DK3732185T3 (da) | 2017-12-29 | 2025-03-31 | Suzhou Ribo Life Science Co Ltd | Konjugater og fremstilling og anvendelse heraf |
| RU2020135289A (ru) | 2018-04-05 | 2022-05-05 | Ф. Хоффманн-Ля Рош Аг | Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в |
| WO2019222479A1 (en) | 2018-05-16 | 2019-11-21 | Alnylam Pharmaceuticals, Inc. | Modified rna agents with reduced off-target effect |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
| WO2019240503A1 (ko) * | 2018-06-12 | 2019-12-19 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| SG11202012759XA (en) | 2018-07-03 | 2021-01-28 | Hoffmann La Roche | Oligonucleotides for modulating tau expression |
| KR20210033004A (ko) | 2018-07-13 | 2021-03-25 | 에프. 호프만-라 로슈 아게 | Rtel1의 발현을 조절하기 위한 올리고뉴클레오티드 |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| EP3903830A4 (en) | 2018-12-28 | 2023-04-26 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE |
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN110218728A (zh) * | 2019-06-28 | 2019-09-10 | 厦门甘宝利生物医药有限公司 | 一种新化合物及其应用 |
| WO2021107097A1 (ja) * | 2019-11-28 | 2021-06-03 | 株式会社ボナック | Ｂ型肝炎治療用核酸分子 |
| WO2021122910A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sbds inhibitors for treating hepatitis b virus infection |
| CN114829599A (zh) | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途 |
| WO2021122993A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of saraf inhibitors for treating hepatitis b virus infection |
| EP4077670A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of cops3 inhibitors for treating hepatitis b virus infection |
| EP4077667A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of sept9 inhibitors for treating hepatitis b virus infection |
| EP4189089A1 (en) * | 2020-07-27 | 2023-06-07 | Aligos Therapeutics, Inc. | Hbv binding oligonucleotides and methods of use |
| CN116157522A (zh) | 2020-08-21 | 2023-05-23 | 豪夫迈·罗氏有限公司 | A1cf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| MX2023005138A (es) * | 2020-11-06 | 2023-06-23 | Arbutus Biopharma Corp | Conjugados dirigidos que comprenden arnpi modificado. |
| EP4265724A4 (en) * | 2020-12-18 | 2025-11-19 | Olix Pharmaceuticals Inc | ARNI AGENT TO INHIBIT THE EXPRESSION AND USE OF HBV |
| US20240309366A1 (en) * | 2020-12-31 | 2024-09-19 | Arcturus Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| CN114767704B (zh) * | 2021-01-21 | 2024-06-14 | 圣诺制药公司 | 一种能够靶向乙型肝炎病毒的药物构造及药物组合物 |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| EP4448106A1 (en) | 2021-12-17 | 2024-10-23 | Hoffmann-La Roche Inc. | Combination of oligonucleotides for modulating rtel1 and fubp1 |
| CN115267193B (zh) * | 2022-09-20 | 2022-12-27 | 北京大学 | 用于判断生物样本中HBsAg来源的方法及系统和用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| WO2003094829A2 (en) | 2002-05-10 | 2003-11-20 | Inex Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
| US20070027099A1 (en) * | 2003-05-19 | 2007-02-01 | Lin Marie C | Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA) |
| HUE042261T2 (hu) | 2003-06-12 | 2019-06-28 | Alnylam Pharmaceuticals Inc | Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák |
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| CN1981033A (zh) | 2004-05-19 | 2007-06-13 | 墨尔本保健公司 | 乙型肝炎的治疗、预防和诊断试剂 |
| JP2008514242A (ja) | 2004-10-01 | 2008-05-08 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 改変型の小さい干渉ｒｎａ分子および使用方法 |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| CN101142316A (zh) | 2005-03-09 | 2008-03-12 | 牧岩生命工学研究所 | 小干扰rna和包含它的用于治疗乙型肝炎的药物组合物 |
| EP2134740A2 (en) | 2007-04-09 | 2009-12-23 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| KR101629017B1 (ko) | 2007-05-22 | 2016-06-10 | 아크투루스 쎄라퓨틱스, 인크. | 히드록시메틸 치환된 ｒｎａ 올리고뉴클레오티드 및 ｒｎａ 복합체 |
| KR20100069679A (ko) | 2007-09-17 | 2010-06-24 | 재단법인 목암생명공학연구소 | ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법 |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| US20100015708A1 (en) * | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
| CA2744093A1 (en) | 2008-12-03 | 2010-06-10 | Marina Biotech, Inc. | Una oligomer structures for therapeutic agents |
| CN102762215A (zh) | 2009-10-16 | 2012-10-31 | 葛兰素集团有限公司 | Hbv反义抑制剂 |
| HUE044815T2 (hu) * | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
| UA118951C2 (uk) | 2011-04-21 | 2019-04-10 | Айоніс Фармасьютікалз, Інк. | Модулювання експресії вірусу гепатиту b (hbv) |
| WO2013003520A1 (en) * | 2011-06-30 | 2013-01-03 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| BR112014010134A2 (pt) | 2011-10-28 | 2019-09-24 | Goethe-University | inibição da expressão genética viral |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| TWI620568B (zh) | 2012-08-30 | 2018-04-11 | 雷普利可公司 | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 |
| US10390276B2 (en) | 2012-12-05 | 2019-08-20 | Nokia Solutions And Networks Oy | Method for traffic steering and network element |
| WO2015050871A2 (en) * | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compounds to treat hepatitis b virus |
| AU2014348212C1 (en) | 2013-11-18 | 2018-11-29 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| WO2015188194A1 (en) | 2014-06-06 | 2015-12-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| BR112017006679A2 (pt) | 2014-10-02 | 2017-12-26 | Protiva Biotherapeutics Inc | moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d |
-
2016
- 2016-07-17 US US15/212,279 patent/US20170016000A1/en not_active Abandoned
- 2016-07-17 CA CA2996722A patent/CA2996722A1/en active Pending
- 2016-07-17 EP EP16828341.4A patent/EP3325097B1/en active Active
- 2016-07-17 WO PCT/US2016/042694 patent/WO2017015175A1/en not_active Ceased
- 2016-07-17 JP JP2018502133A patent/JP6924744B2/ja active Active
- 2016-07-17 CN CN201680053632.1A patent/CN108136206B/zh active Active
- 2016-07-17 AU AU2016296592A patent/AU2016296592B2/en active Active
- 2016-09-10 TW TW105129484A patent/TWI761311B/zh active
-
2018
- 2018-08-30 US US16/117,994 patent/US10961535B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520685A5 (cg-RX-API-DMAC7.html) | ||
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| ES2988612T3 (es) | Agentes de ARNi para la infección por el virus de la hepatitis B | |
| AU2010248239B2 (en) | siRNA conjugate and preparation method thereof | |
| JP2018529732A5 (cg-RX-API-DMAC7.html) | ||
| US8936910B2 (en) | Method for selective oligonucleotide modification | |
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| JP2019504112A5 (cg-RX-API-DMAC7.html) | ||
| JP2017538679A5 (cg-RX-API-DMAC7.html) | ||
| JP2018530529A5 (cg-RX-API-DMAC7.html) | ||
| JP2019533472A5 (cg-RX-API-DMAC7.html) | ||
| CN115516092A (zh) | 血管生成素样3(ANGPTL3)的siRNA及其用途 | |
| JP2016520312A5 (cg-RX-API-DMAC7.html) | ||
| CN113507920A (zh) | 用于乙型肝炎病毒感染的RNAi剂 | |
| JP2017532038A5 (cg-RX-API-DMAC7.html) | ||
| RU2020135289A (ru) | Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в | |
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| WO2012174224A2 (en) | Methods for administering nucleic acid-based therapeutics | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| KR20150006742A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
| TW202237189A (zh) | 具有增強之肝靶向的ｓ抗原運輸抑制寡核苷酸聚合物之接合物 | |
| CN115768439A (zh) | 双链siRNA类似物的缀合物 | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 |